. VertexPharma $VRTX will carry out a potentially $2B expansion of its gene editing presence through deals intended to help the company develop novel treatments for Duchenne MuscularDystrophy and DM1 httpow.lyKiYe50uAshbÂ

. @VertexPharma ($VRTX) will carry out a potentially $2B expansion of its gene editing presence through deals intended to help the company develop novel treatments for #Duchenne #MuscularDystrophy and DM1: http://ow.ly/KiYe50uAshb 

17:55 EDT 10 Jun 2019 | Genetic Engineering News

. @VertexPharma ($VRTX) will carry out a potentially $2B expansion of its gene editing presence through deals intended to help the company develop novel treatments for #Duchenne #MuscularDystrophy and DM1: http://ow.ly/KiYe50uAshb 

More From BioPortfolio on ". @VertexPharma ($VRTX) will carry out a potentially $2B expansion of its gene editing presence through deals intended to help the company develop novel treatments for #Duchenne #MuscularDystrophy and DM1: http://ow.ly/KiYe50uAshb "